NCT04168099 Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
| NCT ID | NCT04168099 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Tanta University |
| Condition | Spontaneous Bacterial Peritonitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2018-12-01 |
| Primary Completion | 2028-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 60 participants in total. It began in 2018-12-01 with a primary completion date of 2028-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis
Eligibility Criteria
Inclusion Criteria: * Patients with spontaneous bacterial peritonitis Exclusion Criteria: * secondary peritonitis
Contact & Investigator
Hala Shaaban El Gendy, Msc
PRINCIPAL INVESTIGATOR
Tanta University - Faculty of Medicine
Frequently Asked Questions
Who can join the NCT04168099 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Spontaneous Bacterial Peritonitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04168099 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 60 participants.
Is NCT04168099 currently recruiting?
Yes, NCT04168099 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.
Where is the NCT04168099 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT04168099 clinical trial?
NCT04168099 is sponsored by Tanta University. The principal investigator is Hala Shaaban El Gendy, Msc at Tanta University - Faculty of Medicine. The trial plans to enroll 60 participants.